氟尿嘧啶、表柔比星与环磷酰胺联合应用对晚期乳腺癌患者抗氧化酶、氨基转移酶和心肌酶水平的影响
|
摘要
目的:探讨氟尿嘧啶、表柔比星与环磷酰胺联合应用(FAC方案)对晚期乳腺癌患者抗氧化酶、氨基转移酶及心肌酶水平的影响。方法:选择2013年1月—2015年1月上海博爱医院收治的晚期乳腺癌患者80例,按照随机数字法分为观察组和对照组,每组各40例。观察组患者采用FAC方案治疗,对照组患者采用多西他赛、环磷酰胺治疗,比较治疗后2组患者氧化应激标志物丙二醛(MDA)、超氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GSH-Px)、丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)、乳酸脱氢酶(LDH)、肌酸激酶(CK)、肌酸激酶同工酶(CK-MB)水平变化情况,最后统计临床治疗效果。结果:治疗后,观察组患者SOD、GSH-Px水平均明显高于对照组,MDA、AST、ALT、LDH、CK及CK-MB水平均明显低于对照组,差异均有统计学意义(P<0.05);观察组患者有效率为70.0%(28/40),明显高于对照组的42.5%(17/40),差异有统计学意义(P<0.05)。结论:采用FAC方案治疗晚期乳腺癌,可降低患者机体氧化应激,减少对心肌及肝脏功能的损伤,提高临床治疗效果。
OBJECTIVE: To investigate the effects of fluorouracil,epirubicin combined with cyclophosphamide( FAC regimen) on level of antioxidant enzyme,aminotransferase and myocardial enzyme of patients with advanced breast cancer. METHODS: 80 patients with advanced breast cancer admitted into Shanghai Bo'ai Hospital from Jan.2013 to Jan. 2015 were selected to be divided into observation group and control group via the random number table,with 40 cases in each. The observation group were given FAC regimen,while the control group were treated with docetaxel and cyclophosphamide. Changes of level of malondialdehyde( MDA), superoxide dismutase( SOD),glutathione peroxidase enzyme( GSH-px),alanine aminotransferase( ALT),aspartate aminotransferase( AST),lactic dehydrogenase( LDH),creatine kinase( CK) and creatine kinase-MB( CK-MB) of two groups were compared,and statistical analysis was conducted on the clinical effects. RESULTS: After treatment,the level of SOD and GSH-px of observation group were significantly higher than those of control group,and the level of MDA,AST,ALT,LDH,CK and CK-MB of observation group were significantly lower than those of control group,with statistically significant difference( P < 0. 05). The total effective rate of observation group was 70. 0%( 28 /40),significantly higher than that of control group [42. 5%( 17 /40) ],with statistically significant difference( P < 0. 05). CONCLUSIONS: FAC regimen in treatment of advanced breast cancer can reduce patients' oxidative stress,myocardial and liver function damages,and improve the clinical treatment effects.
OBJECTIVE: To investigate the effects of fluorouracil,epirubicin combined with cyclophosphamide( FAC regimen) on level of antioxidant enzyme,aminotransferase and myocardial enzyme of patients with advanced breast cancer. METHODS: 80 patients with advanced breast cancer admitted into Shanghai Bo'ai Hospital from Jan.2013 to Jan. 2015 were selected to be divided into observation group and control group via the random number table,with 40 cases in each. The observation group were given FAC regimen,while the control group were treated with docetaxel and cyclophosphamide. Changes of level of malondialdehyde( MDA), superoxide dismutase( SOD),glutathione peroxidase enzyme( GSH-px),alanine aminotransferase( ALT),aspartate aminotransferase( AST),lactic dehydrogenase( LDH),creatine kinase( CK) and creatine kinase-MB( CK-MB) of two groups were compared,and statistical analysis was conducted on the clinical effects. RESULTS: After treatment,the level of SOD and GSH-px of observation group were significantly higher than those of control group,and the level of MDA,AST,ALT,LDH,CK and CK-MB of observation group were significantly lower than those of control group,with statistically significant difference( P < 0. 05). The total effective rate of observation group was 70. 0%( 28 /40),significantly higher than that of control group [42. 5%( 17 /40) ],with statistically significant difference( P < 0. 05). CONCLUSIONS: FAC regimen in treatment of advanced breast cancer can reduce patients' oxidative stress,myocardial and liver function damages,and improve the clinical treatment effects.
引文
[1]杨晓蕾.IGF-I、HGF及胰岛素与乳腺癌患者雌激素受体及淋巴结转移的相关性研究[J].中国实验诊断学,2015,19(3):432-435.
[2]白吉明,李建华,王翔,等.FAC联合化疗对乳腺癌患者抗氧化酶、肝脏转氨酶和心肌酶的影响[J].中国老年学杂志,2016,36(8):1908-1909.
[3]周建炜,杨帆,张浩永.TAC和FAC新辅助化疗方案在乳腺癌保乳术中的疗效比较[J].现代实用医学,2014,26(2):179-181.
[4]刘琦,张新峰,程旭锋,等.参麦注射液防治女性乳腺癌FAC方案心脏毒性临床研究[J].中医学报,2014,29(8):1090-1091,1094.
[5]李永峰,孟旭莉.多基因表达谱预测乳腺癌新辅助化疗疗效研究进展[J].实用肿瘤杂志,2015,30(3):286-290.
[6]丁荣楣,王平,田奕,等.阿瑞匹坦辅助预防乳腺癌FAC方案化疗致恶心呕吐的临床观察[J].疑难病杂志,2015,14(1):45-48.
[7]杜艳林,王泽民,王芳,等.加味逍遥散联合化疗治疗乳腺癌术后疗效观察[J].现代中西医结合杂志,2015,24(3):295-297.
[8]陈江华,赵建华,唐金海,等.环磷酰胺代谢酶基因多态性与乳腺癌化疗反应相关性的探讨[J].中华肿瘤防治杂志,2012,19(10):726-730.
[9]陈焕伟,王博,凌华海,等.高危乳腺癌辅助化疗后白细胞减少的危险因素及其与预后的相关性研究[J].肿瘤药学,2013,3(1):64-69.
[10]王忠,李彬,韩廷超,等.乳腺癌术前经动脉新辅助化学治疗及栓塞的疗效分析[J].实用医学影像杂志,2013,14(4):270-272.
[11]雷林瑜.乳腺癌新辅助化疗病人癌因性疲乏状况的研究[J].医药论坛杂志,2014,35(9):60-61.
[12]杨林,张路.乳腺癌患者手术联合化疗后网织红细胞相关参数的动态监测及临床意义[J].中国老年学杂志,2014,34(21):5997-5999.
[13]马溪近,陈德滇,张季.乳腺癌新辅助化疗的若干问题[J].中国社区医师:医学专业,2013,15(4):49-50.
[14]陈春燕,梁尔斌.益血汤联合化疗在乳腺癌术后的应用效果探讨[J].现代诊断与治疗,2016,27(4):640-642.
[15]吕宇,黄立中,毛丹,等.益气活血化瘀法联合化疗治疗晚期乳腺癌的临床观察[J].中医药学报,2014,42(3):93-96.
[16]冯琼.右丙亚胺联合参芪扶正注射液减轻乳腺癌FAC方案心脏毒性临床研究[J].吉林中医药,2014,34(3):256-259.
[17]张瑾.早期乳腺癌治疗进展荟萃:2012年ASCO年会报道[J].中华乳腺病杂志:电子版,2012,6(5):484-493.
[18]陆翔,陈彩萍,韩文兰.乳腺癌新辅助化疗疗效预测因子的研究进展[J].中华肿瘤防治杂志,2012,19(10):796-800.
[2]白吉明,李建华,王翔,等.FAC联合化疗对乳腺癌患者抗氧化酶、肝脏转氨酶和心肌酶的影响[J].中国老年学杂志,2016,36(8):1908-1909.
[3]周建炜,杨帆,张浩永.TAC和FAC新辅助化疗方案在乳腺癌保乳术中的疗效比较[J].现代实用医学,2014,26(2):179-181.
[4]刘琦,张新峰,程旭锋,等.参麦注射液防治女性乳腺癌FAC方案心脏毒性临床研究[J].中医学报,2014,29(8):1090-1091,1094.
[5]李永峰,孟旭莉.多基因表达谱预测乳腺癌新辅助化疗疗效研究进展[J].实用肿瘤杂志,2015,30(3):286-290.
[6]丁荣楣,王平,田奕,等.阿瑞匹坦辅助预防乳腺癌FAC方案化疗致恶心呕吐的临床观察[J].疑难病杂志,2015,14(1):45-48.
[7]杜艳林,王泽民,王芳,等.加味逍遥散联合化疗治疗乳腺癌术后疗效观察[J].现代中西医结合杂志,2015,24(3):295-297.
[8]陈江华,赵建华,唐金海,等.环磷酰胺代谢酶基因多态性与乳腺癌化疗反应相关性的探讨[J].中华肿瘤防治杂志,2012,19(10):726-730.
[9]陈焕伟,王博,凌华海,等.高危乳腺癌辅助化疗后白细胞减少的危险因素及其与预后的相关性研究[J].肿瘤药学,2013,3(1):64-69.
[10]王忠,李彬,韩廷超,等.乳腺癌术前经动脉新辅助化学治疗及栓塞的疗效分析[J].实用医学影像杂志,2013,14(4):270-272.
[11]雷林瑜.乳腺癌新辅助化疗病人癌因性疲乏状况的研究[J].医药论坛杂志,2014,35(9):60-61.
[12]杨林,张路.乳腺癌患者手术联合化疗后网织红细胞相关参数的动态监测及临床意义[J].中国老年学杂志,2014,34(21):5997-5999.
[13]马溪近,陈德滇,张季.乳腺癌新辅助化疗的若干问题[J].中国社区医师:医学专业,2013,15(4):49-50.
[14]陈春燕,梁尔斌.益血汤联合化疗在乳腺癌术后的应用效果探讨[J].现代诊断与治疗,2016,27(4):640-642.
[15]吕宇,黄立中,毛丹,等.益气活血化瘀法联合化疗治疗晚期乳腺癌的临床观察[J].中医药学报,2014,42(3):93-96.
[16]冯琼.右丙亚胺联合参芪扶正注射液减轻乳腺癌FAC方案心脏毒性临床研究[J].吉林中医药,2014,34(3):256-259.
[17]张瑾.早期乳腺癌治疗进展荟萃:2012年ASCO年会报道[J].中华乳腺病杂志:电子版,2012,6(5):484-493.
[18]陆翔,陈彩萍,韩文兰.乳腺癌新辅助化疗疗效预测因子的研究进展[J].中华肿瘤防治杂志,2012,19(10):796-800.